Showing results (251-260 of 1,098) with videos related to
Sort By:
Pageof 110
Pharmaceuticals (Basel, Switzerland)|August 28, 2025
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-AnalysisTingyang Wei, Zonglin Li, Chu Lin, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or ObesityLinong Ji, Jie Liu, Zhi Jin Xu, et al.Diabetes, Obesity & Metabolism|September 23, 2024
Cofrogliptin once every 2 weeks as add-on therapy to metformin versus daily linagliptin in patients with type 2 diabetes in China: A randomized, double-blind, non-inferiority trialQian Ren, Ling Li, Xiuhai Su, et al.Diabetes Research and Clinical Practice|December 17, 2023
Incidence and trends of type 1 diabetes before and after 2000 in the Western Pacific Region: A systematic review and meta-analysisDu Wang, Xiaoli Hou, Juan Huang, et al.Journal of Diabetes|June 2, 2016
Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASSLinong Ji, Qing Su, Bo Feng, et al.Diabetes/Metabolism Research and Reviews|March 21, 2019
Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohortXianghai Zhou, Yufeng Li, Xiuying Zhang, et al.Endocrine Connections|January 22, 2020
Factors associated with resistance to complications in long-standing type 1 diabetes in ChinaWei Liu, Yanai Wang, Xueyao Han, et al.Endocrine Connections|September 22, 2022
Preserved C-peptide secretion is associated with higher time in range (TIR) on intermittently scanned continuous glucose monitoring in Chinese adults with type 1 diabetesWei Liu, Yunke Ma, Xiaoling Cai, et al.Expert Opinion on Investigational Drugs|August 15, 2022
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participantsZonglin Li, Chu Lin, Jinyu Zhou, et al.Diabetes, Obesity & Metabolism|February 22, 2023
Population attributable fractions of modifiable risk factors for microvascular complications of type 2 diabetes in China: An analysis using national cross-sectional dataChu Lin, Xingyun Zhu, Ruoyang Jiao, et al.Pageof 110